Blog
RSS FeedPosted by Michael Wonder on 06 Jul 2025
Garadacimab for the prevention of recurrent attacks of hereditary angioedema in patients 12 years of age and older
2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Jul 2025
Teprotumumab for the treatment of patients with thyroid eye disease
2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Jul 2025
Adagrasib for adults with previously treated, advanced, KRAS G12C mutation positive non-small-cell lung cancer
2 July 2025 - NICE is unable to make a recommendation on the use of adagrasib (Krazati) for the second-line treatment ...
Posted by Michael Wonder on 01 Jul 2025
NICE welcomes the inclusion of measures for equal treatment of medicines and health technologies
1 July 2025 - The new approach will ensure that high impact devices, diagnostics and digital tools recommended by NICE, that ...
Posted by Michael Wonder on 29 Jun 2025
Pegzilarginase for the treatment of patients 2 years of age and older with arginase-1 deficiency
26 June 2025 - NICE has published additional draft guidance consultation on the use of pegzilarginase in the NHS in ...
Posted by Michael Wonder on 19 Jun 2025
Final draft guidance finds benefits of two treatments for patients with Alzheimer’s disease remain too small to justify the additional cost to the NHS
19 June 2025 - The benefits from donanemab (Kisunla; Eli Lilly) and lecanemab (Leqembi; Eisai) - remain too small to justify ...
Posted by Michael Wonder on 19 Jun 2025
Tislelizumab for the treatment of adults with advanced non-small-cell lung cancer after platinum-based chemotherapy
19 June 2025 - NICE is unable to make a recommendation on the use of tislelizumab (Tevimbra) for the treatment of ...
Posted by Michael Wonder on 19 Jun 2025
Atezolizumab for the adjuvant treatment of patients with resected non-small-cell lung cancer
19 June 2025 - NICE has published final evidence-based recommendations on the use of atezolizumab (Tecentriq) for the adjuvant treatment ...
Posted by Michael Wonder on 18 Jun 2025
Obecabtagene autoleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia
13 June 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 14 Jun 2025
NICE leads the way in approving breakthrough treatment for multiple myeloma
13 June 2025 - People in England will become the first in the world to receive belantamab mafodotin for this indication ...
Posted by Michael Wonder on 23 May 2025
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
23 May 2025 - New treatment sparsentan has been found to slow down the progression of kidney damage, which will change ...
Posted by Michael Wonder on 22 May 2025
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
22 May 2025 - Dostarlimab, when used in combination with platinum-based chemotherapy, can be used as an option for the ...
Posted by Michael Wonder on 21 May 2025
New weekly treatment option approved for patients with haemophilia B
21 May 2025 - Final draft guidance published today recommends marstacimab (Hympavzi; Pfizer) for treating severe haemophilia B in patients ...
Posted by Michael Wonder on 15 May 2025
Deal agreed for continued access to life-changing treatment for rare inherited disease
14 May 2025 - NICE is consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2, ...
Posted by Michael Wonder on 15 May 2025
Health inequalities - an update to NICE’s methods for health technology evaluation
14 May 2025 - Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in ...